A $6,922.62 sticker price now comes with a $950 alternative on a federal website. TrumpRx, the Trump administration’s drug-price site, lists AbbVie’s Humira pen at $950 for cash-paying patients. The discount is a pharmacy coupon, not a plan rate, and its conditions matter most to patients on Medicare.
The coupon behind the $950
The Humira Pen page on TrumpRx.gov shows “Starting at $950.00” against an original price of $6,922.62, a difference of $5,972.62 that the site labels 86% off. The product is AbbVie’s adalimumab pen, 40 mg per 0.4 mL, with a quantity of 2 count. The page does not say whether the $950 covers one pen or the whole two-count carton, so it is not a monthly price. The same $950.00 and $6,922.62 pair appears on the site’s browse listing.
The way to use it is at a pharmacy counter. The page says the coupon is “widely supported at retail pharmacies that dispense Humira Pen,” and the coupon cannot be viewed until the user accepts its terms. A patient needs a valid prescription from an independent, third-party prescriber and must be a U.S. resident, in Washington, D.C., or in a U.S. territory. For pharmacy questions about processing the coupon online, the page lists a help desk at 1-800-364-4767.
Who the coupon is for, and who it is not
The offer is for self-paying patients. TrumpRx’s description spells out that the card “is not insurance,” that the cash price “cannot be combined with benefits offered by” insurance, and that it does not count toward deductibles or out-of-pocket maximums. People enrolled in a government program must tell their plan about cash purchases, and the page says Medicare Part D enrollees must not submit these purchases toward their True Out-of-Pocket costs.
That last clause is the one that separates Medicare patients from everyone else. Part D has a yearly limit on what a member pays for covered drugs. Medicare.gov puts it at $2,100 in 2026 and $2,400 in 2027, after which a member moves into catastrophic coverage. A plan member who pays $950 through the coupon pays outside that system, and the $950 does not move the member toward the $2,400 mark. For a patient whose plan covers Humira, the question is a comparison, not a discount: what the plan charges for the same pen, what the yearly limit would cap, and what $950 buys with no credit toward that limit.
A $950 Humira coupon price earns no credit toward the Part D out-of-pocket limit, so the cash price and the plan price have to be weighed against each other. The Medicare Cost & Coverage Protection Kit explains the new Part D out-of-pocket cap and includes 51 state Medicare cost-help packs for readers deciding between the two.
Weigh the $950 Humira coupon against Part D limits with the Cost & Coverage Protection Kit →
Terms AbbVie can change
The price is not locked. The page says the savings are “set in AbbVie’s sole discretion and may be changed with or without notice at any time for any reason.” AbbVie may also end or amend the program at any time and may remove participants it considers ineligible. A $950 figure on one day is a snapshot of a coupon AbbVie controls.
The same wording applies to eligibility. AbbVie keeps the right to remove any participant it considers ineligible, and the coupon stays hidden until the patient accepts its terms. Pharmacy questions about processing the coupon go to the help desk the page lists.
The deal in the background
The listing did not arrive in isolation. PharmaLive reported that AbbVie put Humira on TrumpRx “at steep discount as tariff threat solidifies,” giving the price as around $950, roughly an 86% discount to its usual price. The publication tied the listing to AbbVie’s $100 billion research and manufacturing pledge, announced as tariffs on drugmakers loomed. The figure is a company pledge, and the TrumpRx page itself says nothing about it.
That context explains why a single brand-name biologic is on the site at all, but it does not change what a patient pays at the counter. The patient-facing facts are the ones on the TrumpRx page: a coupon, a cash price and a long list of exclusions.
Putting the $950 price next to a Part D cost
The comparison is simple to start. The first free number is the plan’s own price for the Humira pen: the member’s Part D plan or Medicare Advantage drug plan can quote a copay or coinsurance for the exact product and quantity. That goes beside the coupon price on TrumpRx.gov, read for the same pen and count.
Three questions settle most of it: whether Humira is on the plan’s formulary and whether it needs prior authorization, how much of the yearly limit has been spent so far this year, and what the pharmacy charges with the coupon in hand. A patient who has already spent close to the 2026 limit of $2,100 may owe little for the rest of the year through the plan, while a patient early in the year faces a different calculation. Medicare.gov adds one more route: people with Medicaid, a Medicare Savings Program or SSI get Extra Help automatically, and payments made through that program count toward the limit.
The coupon terms themselves are AbbVie’s, and they can change without notice, so the price shown on TrumpRx.gov on the day of the purchase is the one that counts.
A $950 coupon that earns no Part D credit
The detail people miss is that the coupon price sits outside the plan, so $950 spent at the counter does not shorten the road to the yearly limit. The Medicare Cost & Coverage Protection Kit explains the new Part D out-of-pocket cap and includes 51 state Medicare cost-help packs, so a patient can see what the plan would charge and what state programs add before choosing the cash price. The guide runs 15 pages.
Get the Part D cap explainer and state help packs in the Cost & Coverage Protection Kit →
This article was produced with AI assistance and reviewed by The Financial Wire’s editorial team.
Warren Cohen is a finance writer based in Phoenix, Arizona, covering personal finance topics including credit, banking, and beginner investing. He earned his degree in business administration from Arizona State University and began his career working in consumer finance, where he gained direct experience with lending and credit systems. He now writes for personal finance websites and fintech platforms, focusing on clear, practical content that helps readers make informed financial decisions.
